FDA announced a draft guidance that describes its policy on public warning and notification of recalled products. The guidance outlines: ● circumstances when a company should issue a public warning about a recall ● the general timeline for companies to issue such a warning ● what information should be included in a public warning, and ● situations where the FDA may take its own action. More can be read about changes made to the weekly web-based Enforcement Report on the FDA blog.
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
